Survanta (Beractant) is used to treat hyaline membrane disease. Survanta effectiveness has fully been confirmed by medics. Beractant is administered into the body as an injection. This condition mostly affects premature neonates who require ventilation. This condition can only be determined by a radiograph. A follow-up of about 24 months is encouraged after using Survanta.